Neoplasms, Nerve Tissue  >>  Inlyta (axitinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inlyta (axitinib) / Pfizer
NCT00094107: Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

Completed
2
32
US, Europe
Axitinib [AG-013736]
Pfizer
Melanoma, Skin Neoplasms
04/08
04/08
NCT01508117: Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients

Terminated
2
1
US
Axitinib, AG-013736, Radiation Therapy, Hypofractionated radiation therapy
University of Cincinnati, Pfizer
Glioblastoma Multiforme
10/12
10/12
NCT01435122: A Study of Axitinib in Advanced Carcinoid Tumors

Completed
2
30
US
Axitinib, AG013736, selective inhibitor of receptor tyrosine kinases
H. Lee Moffitt Cancer Center and Research Institute, National Comprehensive Cancer Network, Pfizer
Carcinoid Tumor
01/17
02/18
AxiGII, NCT01562197: A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ESMO-ECCO-ESTRO 2013
Sep 2013 - Sep 2013: ESMO-ECCO-ESTRO 2013
Completed
2
56
Europe
axitinib, Inlyta (TM), Axitinib plus Lomustine, CCNU
Bart Neyns, Pfizer
Glioblastoma Multiforme
08/18
12/18

Download Options